NuCana Announces Grant Of Composition-Of-Matter Patent For NUC-7738 In The U.S.
Portfolio Pulse from Benzinga Newsdesk
NuCana plc (NASDAQ:NCNA) has been granted a new composition-of-matter patent for its anti-cancer agent NUC-7738 by the USPTO. This strengthens its intellectual property portfolio, which includes over 80 patents globally. NUC-7738 is in Phase 2 trials for melanoma treatment.
September 25, 2024 | 8:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NuCana's new US patent for NUC-7738 enhances its IP protection, potentially increasing investor confidence. The drug is in Phase 2 trials, showing promise in melanoma treatment.
The issuance of a new patent for NUC-7738 enhances NuCana's intellectual property protection, which is crucial for biotech companies. This development could boost investor confidence, especially given the promising Phase 2 trial results for melanoma treatment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100